Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/24/2008 First Published: 9/24/2008


1.		Phase I/II Pilot Study of Cholecalciferol and Genistein in Patients Undergoing Palliative External Beam Radiotherapy for Osseous Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Temporarily closed				18 and over				NCI				UMN-2008LS035 UMN-2008LS035, UMN-0803M29541, NCT00769990

Last Modified: 6/10/2008 First Published: 3/24/2003


2.		Phase II Study of Genistein in Patients With Localized Prostate Cancer and Planned Radical Prostatectomy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NU-00U7 NCT00058266

Last Modified: 6/24/2008 First Published: 6/25/2005


3.		Phase II Randomized Study of Neoadjuvant Genistein in Patients Undergoing Surgical Resection for Bladder Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Closed				18 and over				NCI				WCCC-CO-04307 WCCC-UWI03-1-01, WCCC-H-2005-0026, NCT00118040

Last Modified: 1/8/2009 First Published: 10/21/2005


4.		Phase II Study of Gemcitabine Hydrochloride and Genistein in Women With Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				WSU-C-2597 NCT00244933

Last Modified: 1/14/2008 First Published: 1/6/2006


5.		Phase II Pilot Study of Genistein and High-Dose Interleukin-2 in Patients With Metastatic Malignant Melanoma or Renal Clear Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				NU-04V1 CHIR-NU-04V1, NU-IRB-0310-083, NCT00276835

Last Modified: 8/15/2008 First Published: 2/3/2006


6.		Phase II Randomized Study of Genistein in Women At High Risk For Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Closed				25 and older				NCI				NU-NWU03-1-04 NU-NCI-04B3, NU-0835-030, NCT00290758, NWU03-1-04

Last Modified: 8/23/2008 First Published: 9/10/2006


7.		Phase II Study of Genistein, Gemcitabine Hydrochloride, and Erlotinib Hydrochloride in Patients With Locally Advanced or Metastatic Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Temporarily closed				21 and over				NCI				WSU-2005-006 WSU-025806MP4F, NCT00376948


8.		Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Closed				18 and over				Other				P2BV10 NCT00546039

Last Modified: 5/1/2001 First Published: 8/1/1998


9.		Phase I Randomized Study of Genistein for Prevention of Cancer in Patients With No History of Cancer or With Asymptomatic Early Prostate Cancer or Other Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Prevention, Treatment				Completed				18 and over				NCI				NCI-98-C-0099B

Last Modified: 6/12/2007 First Published: 6/1/2000


10.		Phase I Randomized Study of Genistein in Patients With Stage II, III, or IV Prostate Cancer (Summary Last Modified 08/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				40 and over				NCI				UNC-LCCC-9711 UNC-GCRC-1203, NCI-G00-1788, NCT00005827

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute